References in periodicals archive ?
Thus, serum KIM-1 may be recommended as a biomarker for detecting early diabetic nephropathy.14,16,17-20 KIM-1 levels in this study showed strong positive association with blood urea nitrogen as a marker for kidney function both at baseline (r= 0.728; p value = 0.000) and follow up (r=0.843; p value = 0.001).
FREE Latest SAMPLE COPY OF "Diabetic Nephropathy Market Research Report- Global forecast till 2023" @ https://www.marketresearchfuture.com/sample_request/5664
Identifying parameters to distinguish non-diabetic renal diseases from diabetic nephropathy in patients with type 2 diabetes mellitus: A meta-analysis.
As far as treatment is concerned; Angiotensin converting enzyme (ACE) inhibitors and Angiotensin receptor blockers (ARB) both are equally effective in the treatment of diabetic nephropathy in patients with type 1 or type 2 diabetes mellitus.
Lupus nephritis was the most common among secondary GN (68.6%), followed by diabetic nephropathy (22.5%); membranous nephropathy was the most common primary GN (30.0%), followed by IgA nephropathy (16.6%) (Figure 2).
Blood urea nitrogen, serum creatinine, formulas to estimated glomerular filtration rate (GFR), proteinuria, and albuminuria are measures currently used to assess the presence and progress of diabetic nephropathy [2,3].
Diabetic nephropathy affects the African-American population about 3-5 times more than the Caucasian population.
Glycosylation of tissue proteins may contribute to diabetic nephropathy apart from other microvascular complications.
announced that it will initiate a Phase II clinical trial investigating IW-1973 in diabetic nephropathy. IW-1973 is an investigational soluble guanylate cyclase (sGC) stimulator which plays an important role in regulating diverse physiological processes such as blood flow, inflammation, fibrosis, and metabolism.
Diabetic nephropathy is the leading cause of End Stage Renal Disease (ESRD) worldwide and a leading cause of DM-related morbidity and mortality.
Diabetic nephropathy (DN) is one of the most important microvascular complications of DM and is responsible for 40-50% of all cases of end stage renal disease (ESRD) [1].